---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038867"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:42:49.027919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025

## Summary
- Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).
- Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.
- Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.
- Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.
- Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled.

## SEC filing metadata
- accession: 0001628280-25-038867
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/0001628280-25-038867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/arwr-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038867
- JSON: https://secwatch.observer/filing/0001628280-25-038867.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.